In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems

Magenheim, 1991, Nanoparticle characterization:a comprehensive physicochemical approach, S T P Pharm Sci, 1, 221 Duncan, 2005, Nanomedicine gets clinical, Materials Today, 8, 16, 10.1016/S1369-7021(05)71032-4 Nel, 2006, Toxic potential of materials at the nanolevel, Science, 311, 622, 10.1126/science.1114397 Panyam, 2003, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv Drug Deliv Rev, 55, 329, 10.1016/S0169-409X(02)00228-4 Stone, 2006, Nanotoxicology: signs of stress, Nat Nanotechnol, 1, 23, 10.1038/nnano.2006.69 Li, 2008, The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles, Free Radic Biol Med, 44, 1689, 10.1016/j.freeradbiomed.2008.01.028 Oberdorster, 2005, Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy, Particle Fibre Toxicol, 2, 8, 10.1186/1743-8977-2-8 McNeil, 2005, Nanotechnology for the biologist, J Leukocyte Biol, 78, 585, 10.1189/jlb.0205074 Liversidge, 1995, Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, Int J Pharm., 125, 91, 10.1016/0378-5173(95)00122-Y Desai, 1996, Gastrointestinal uptake of biodegradable microparticles: effect of particle size, Pharm Res, 13, 1838, 10.1023/A:1016085108889 Wilkinson, 2006, Roadmapping medical devices, Medical Device Link, 6, 1 Koziara, 2003, In situ blood brain barrier transport of nanoparticles, Pharm Res, 20, 1772, 10.1023/B:PHAM.0000003374.58641.62 Lamprecht, 1999, Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification, Int J Pharm, 184, 97, 10.1016/S0378-5173(99)00107-6 Brunauer, 1938, Adsorption of gases in multimolecular layers, J Am Chem Soc, 60, 309, 10.1021/ja01269a023 Merget, 2002, Health hazards due to the inhalation of amorphous silica, Arch Toxicol, 75, 625, 10.1007/s002040100266 Vergoni, 2009, Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution, Nanomed Nanotechnol Biol Med, 5, 369, 10.1016/j.nano.2009.02.005 Tosi, 2007, Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123, J Control Release, 122, 1, 10.1016/j.jconrel.2007.05.022 Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials, 21, 2475, 10.1016/S0142-9612(00)00115-0 Campbell, 1995, 365 Lockman, 2002, Nanoparticle technology for drug delivery across the blood-brain barrier, Drug Dev Ind Pharm, 28, 1, 10.1081/DDC-120001481 Storm, 1995, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Adv Drug Deliv Rev, 17, 31, 10.1016/0169-409X(95)00039-A Torchilin, 1995, Which polymers can make nanoparticulate drug carriers long-circulating?, Adv Drug Deliv Rev, 16, 141, 10.1016/0169-409X(95)00022-Y